Assignee
LYELL IMMUNOPHARMA INC
US·5 granted patents·16 pending applications·0 citations·filing 2021–2025
Top patents by PatentIndex Score
21 records- 0170US2024409610A1Novel Recombinant Cell Surface MarkersLYELL IMMUNOPHARMA INC·Filed 2024·Application pending·0 cites
- 0268US2026098075A1Chimeric antigen receptor spacersLYELL IMMUNOPHARMA INC·Filed 2025·Application pending·0 cites
- 0367US2025154458A1Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T CellsLYELL IMMUNOPHARMA INC·Filed 2024·Application pending·0 cites
- 0466US12270032B2Codon-optimized nucleotide sequences encoding an AP-1 transcription factorLYELL IMMUNOPHARMA INC·Filed 2022·Granted Apr 8, 2025·0 cites·20 claims
- 0563US12054531B2Recombinant cell surface markersLYELL IMMUNOPHARMA INC·Filed 2021·Granted Aug 6, 2024·0 cites·28 claims
- 0662US12091682B2Methods for making, compositions comprising, and methods of using rejuvenated T cellsLYELL IMMUNOPHARMA INC·Filed 2021·Granted Sep 17, 2024·0 cites·32 claims
- 0761US12144827B2ROR1 targeting chimeric antigen receptorLYELL IMMUNOPHARMA INC·Filed 2022·Granted Nov 19, 2024·0 cites·20 claims
- 0858US2026008999A1Methods for culturing cellsLYELL IMMUNOPHARMA INC·Filed 2025·Application pending·0 cites
- 0958US2026083846A1Polynucleotides targeting nr4a3 and uses thereofLYELL IMMUNOPHARMA INC·Filed 2023·Application pending·0 cites
- 1057US12365871B2Methods for culturing cellsLYELL IMMUNOPHARMA INC·Filed 2021·Granted Jul 22, 2025·0 cites·32 claims
- 1157US2025228939A1Enhanced immune cell therapyLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1256US2021380658A1Chimeric antigen receptor spacersLYELL IMMUNOPHARMA INC·Filed 2021·Application pending·0 cites
- 1355US2025297268A1Codon-optimized nucleotide sequences encoding an ap-1 transcription factorLYELL IMMUNOPHARMA INC·Filed 2025·Application pending·0 cites
- 1451US2023313138A1Methods for culturing cells expressing c-junLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1551US2023310605A1Methods for culturing cells expressing ror1-binding proteinLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1650US2023052243A1Nr4a-deficient cells expressing c-jun and uses thereofLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1750US2024374725A1Nr4a3-deficient immune cells and uses thereofLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1850US2023398216A1Chimeric activation receptorsLYELL IMMUNOPHARMA INC·Filed 2021·Application pending·0 cites
- 1949US2023181644A1Methods of generating cellsLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 2046US2022175834A1Methods for culturing immune cellsLYELL IMMUNOPHARMA INC·Filed 2021·Application pending·0 cites
- 2146US2024228957A9Methods for culturing cellsLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →